interdisciplinary specialist palliative care in reducing symptom burden and detecting distress in patients with high intensity scores. Their team consistently used 2 validated tools at patient encounters: the Edmonton Symptom Assessment System (ESAS) and the
Search Results
Palliative Care: Who is Responsible?
Amanda M. Rosenblum and Martin R. Chasen
Validating a Patient-Reported Outcomes–Derived Algorithm for Classifying Symptom Complexity Levels Among Patients With Cancer
Linda Watson, Siwei Qi, Andrea DeIure, Eclair Photitai, Lindsi Chmielewski, and Louise Smith
Background For patients with cancer, experiencing multiple concurrent symptoms is common. 1 – 4 This concept has been described in a variety of ways, such as symptom clusters, symptom burden, or complex symptoms. Although these terms have similar
Impact of Psychological Distress on Treatment Timeliness in Oncology Patients at a Safety-Net Hospital
Sheshadri Madhusudhana, Michelle Gates, Daulath Singh, Punita Grover, Mahathi Indaram, and An-Lin Cheng
poorer survival, this likely reflects the preferential initiation of immediate treatment for patients with poorer prognoses and greater symptom burden at diagnosis, such as in the case of advanced lung cancer. 7 , 8 Previous research on treatment
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Aaron T. Gerds, Jason Gotlib, Haris Ali, Prithviraj Bose, Andrew Dunbar, Amro Elshoury, Tracy I. George, Krishna Gundabolu, Elizabeth Hexner, Gabriela S. Hobbs, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Animesh Pardanani, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Brady L. Stein, Moshe Talpaz, Pankit Vachhani, Martha Wadleigh, Sarah Wall, Dawn C. Ward, Mary Anne Bergman, and Cindy Hochstetler
However, certain aspects of clinical management regarding the diagnosis, assessment of symptom burden, and selection of appropriate symptom-directed therapies continue to present challenges for hematologists and oncologists. 11 Molecular
Implementing Routine Screening for Distress, the Sixth Vital Sign, for Patients With Head and Neck and Neurologic Cancers
Barry D. Bultz, Amy Waller, Jodi Cullum, Paula Jones, Johan Halland, Shannon L. Groff, Catriona Leckie, Lisa Shirt, Scott Blanchard, Harold Lau, Jacob Easaw, Konrad Fassbender, and Linda E. Carlson
Cancer Centre. Although these clinics are relatively small, patients often report high levels of symptom burden, needs, and concerns. 16 , 17 Few studies have examined the benefits of psychosocial interventions in these tumor groups. 16 , 17 The current
Palliative Care, Version 1.2014
Michael H. Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Susan Block, Shirley N. Codada, Shalini Dalal, Maria Dans, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Todd M. Sauer, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Carin Van Zyl, Sharon M. Weinstein, Mary Anne Bergman, and Jillian L. Scavone
of NCCN®. Palliative care has been shown to reduce symptom burden, improve quality of life, and increase the odds of dying at home. In a recent study comparing standard care with ongoing palliative care in patients with advanced cancer and a
Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care
Deena R. Levine, Liza-Marie Johnson, Angela Snyder, Robert K. Wiser, Deborah Gibson, Javier R. Kane, and Justin N. Baker
were significant differences in the use of PC among various clinical services, which suggested that symptom burden was underestimated in certain diagnostic groups. 17 Although the underestimation of symptom burden and underutilization of PC services
Asking “How Are You?”
Stewart B. Fleishman
intended to become a symptom-burden or quality-of-life assessment tool. Because the committee members each had day jobs, and funding for such a nascent program was limited from within NCCN and extramurally, it took many meetings and lots of compromise and
The Need for United States–Based Guidelines for Myeloproliferative Neoplasms
Brady L. Stein, Susan O’Brien, Peter Greenberg, and Ruben A. Mesa
symptom burden is increasing, and accordingly, focus on symptom-directed therapy, which served as a basis for approval of JAK inhibitors, is also increasing. An MPN guideline can emphasize the need for symptom assessment when planning therapy, and outline
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Ruben Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Aaron T. Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Rebecca B. Klisovic, Patricia Kropf, Sanjay R. Mohan, Stephen Oh, Eric Padron, Nikolai Podoltsev, Daniel A. Pollyea, Raajit Rampal, Lindsay A. M. Rein, Bart Scott, David S. Snyder, Brady L. Stein, Srdan Verstovsek, Martha Wadleigh, Eunice S. Wang, Mary Anne Bergman, Kristina M. Gregory, and Hema Sundar
development of targeted therapies, which have resulted in significant improvements in disease-related symptoms and quality of life. 7 , 8 However, certain aspects of clinical management regarding diagnosis, assessment of symptom burden, and selection of